SERENA-6: First-line camizestrant plus CDK4/6 inhibitor for emerging ESR1-mutated breast cancer shows consistent benefit in PROs
Breast Cancer
ESMO 2025
Related content
CHICAGO 2025
Breast Cancer
LBA4: SERENA-6: Switching to camizestrant plus CDK4/6 inhibitor significantly delays progression in HR-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation in first line
Breast Cancer
Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy
Ann Oncol
Mayer EL, Bidard FC, Park YH, Janni W, Ma C, Cristofanilli M, Iwata H, Bianchini G, Kalinsky K, Chia S, Brufsky A, Fasching PA, Nowecki Z, Chen SC, Pascual J, Moreau L, Ruiz-Borrego M, Shai A, Karadurmus N, Sohn JH, Zhu Y, Leddin I, Miralles MS, Bartlett CH, Turner N
doi: 10.1016/j.annonc.2025.10.006
COMMENTED
Breast Cancer
Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial
★ 1
Recommended and commented by
Dr Andreas Müller, Faculty Member
J Natl Cancer Inst
Wortelboer N, Kent S, Blommestein HM, van Ommen-Nijhof A, van der Noort V, van den Pol E, Páez CG, Beeker A, Beelen K, Hamming LC, Heijns JB, Honkoop AH, de Jong PC, van Rossum-Schornagel QC, van de Mheen CVS, Tol J, Driel CST, Vrijaldenhoven S, van Leeuwen-Stok AE, Sonke GS, Jager A, Konings IR
doi: 10.1093/jnci/djaf334
Breast Cancer
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer
Eur J Cancer
Michel LL, Ziegler P, Kreis P, Hartkopf AD, Wallwiener M, Häberle L, John N, Kolberg HC, Hadji P, Tesch H, Ettl J, Lüftner D, Müller V, Belleville E, Wimberger P, Enzinger HM, Huebner H, Uhrig S, Hack CC, Krabisch P, Fasching PA, Wuerstlein R, Untch M, Ditsch N, Hein A, Janni W, Taran FA, Lux MP, Wallwiener D, Brucker SY, Fehm TN, Schneeweiss A, Goossens C, Engler T
doi: 10.1016/j.ejca.2025.115689
Breast Cancer
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial
Eur J Cancer
Wortelboer N, Kent S, Konings IR, van Ommen-Nijhof A, van der Noort V, van den Pol E, Guerrero Páez C, van Bekkum ML, van den Berkmortel FWPJ, Droogendijk HJ, Houtsma D, Oosterkamp HM, van der Padt-Pruijsten A, Siemerink EJM, Tol J, van Zweeden AA, van Leeuwen-Stok AE, Sonke GS, Jager A, Blommestein HM
doi: 10.1016/j.ejca.2025.116051
SABCS 2025
Breast Cancer
DESTINY-Breast09: Favorable PROs with T-DXd plus pertuzumab in first-line HER2-positive advanced and metastatic breast cancer
Lung, Respiratory and Thoracic Cancer
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF(V600E)-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study
Lancet Oncol
Di Federico A, Wang K, Chen MF, Barsouk AA, Pagliaro A, Chen LN, Ogliari FR, Stockhammer P, Thawani R, Raslan S, Gariazzo E, Fusco F, Hambelton GM, Citarella F, Meyer D, Aldea M, De Giglio A, Alessi JV, Pecci F, Gelsomino F, Corassa M, Vokes NI, Wang X, de Biase D, Abu Rous F, Areesawangkit P, Elghawy O, Cortellini A, Metro G, Ferrara R, Awad MM, Pabani A, Murray JC, Cappuzzo F, Garassino MC, Dagogo-Jack I, Riely G, Grant M, Herzberg BO, Ardizzoni A, Planchard D, Johnson BE, Langer CJ, Offin M, Negrao MV, Ricciuti B
doi: 10.1016/S1470-2045(25)00409-7
SABCS 2025
Breast Cancer
NATALEE: Long-term data show sustained clinical benefit with ribociclib plus an NSAI in HR-positive, HER2-negative early breast cancer
ESMO 2025
Breast Cancer